Company news

Aquestive Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8: 00 a.m. ET

October 13, 2021

Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement

October 5, 2021

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.

September 28, 2021

Aquestive Therapeutics to Participate in Three Investor Conferences in September

September 6, 2021

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement

August 8, 2021

Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference

August 5, 2021

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance

August 2, 2021

Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8: 00 a.m. ET

July 20, 2021

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film

July 18, 2021

Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film

June 23, 2021

Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer

June 20, 2021

Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences

June 8, 2021

Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference

May 10, 2021

Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8: 00 a.m. ET

April 20, 2021

Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

March 24, 2021

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 8, 2021

Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9: 00 a.m. ET

March 4, 2021

Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback

February 24, 2021

Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8: 00 a.m. ET

February 16, 2021

Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

February 8, 2021

Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

January 27, 2021

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

January 20, 2021

Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

January 3, 2021

Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer

December 15, 2020

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

November 24, 2020

Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization

November 22, 2020

Aquestive Therapeutics Completes FDA Type A Meeting on Libervant

November 17, 2020

Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 3, 2020

Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million

November 2, 2020

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8: 00 a.m. ET

October 13, 2020

Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

September 24, 2020

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

August 19, 2020

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

August 9, 2020

Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches

August 3, 2020

Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

July 27, 2020

Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8: 00 a.m. ET

July 14, 2020

Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

June 28, 2020

Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

June 15, 2020

Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

June 3, 2020

Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval

May 20, 2020

Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference

May 6, 2020

Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track

May 4, 2020

Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6

April 20, 2020

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

March 10, 2020

Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020

February 19, 2020

Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film

February 9, 2020

Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

February 5, 2020

Aquestive Therapeutics Receives FDA Response to Citizen’s Petition

January 11, 2020

Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance

January 9, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.